NCT07269587Active, not recruiting
A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19
A Retrospective, Observational, and Multicenter Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19
Source: ClinicalTrials.gov · Last updated 10 Dec 2025
Brief summary (registry, in English)
This clinical study is a retrospective, observational, and multicenter post marketing real-world study aimed at evaluating the efficacy and safety of CNCT-19 in the treatment of Chinese adult B-cell acute lymphoblastic leukemia patients.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 275 (actual)
- First submitted
- 25 Nov 2025
- Start date
- 7 Nov 2025
- Primary completion date
- 30 Nov 2027
- Lead sponsor
- Ruijin Hospital
- NCT number
- NCT07269587
What you commit to
- Study type: Observational
- Participants enrolled: 275
- From 7 Nov 2025 to the primary completion date, 30 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals with acute graft-versus-host disease (GVHD) or moderate to severe chronic GVHD within the first 4 weeks of screening; Individuals who have received systemic drug therapy for GVHD within the past 4 weeks prior to reinfusion;
Other illness
- Active systemic autoimmune diseases during treatment;
- Those who meet any of the following criteria:
- Positive hepatitis B surface antigen (HBsAg) and/or hepatitis B e antigen (HBeAg);
- hepatitis B e antibody (HBe Ab) and/or hepatitis B core antibody (HBc Ab) are positive, and the number of HBV-DNA copies is greater than the measurable lower limit;
- Hepatitis C antibody (HCV Ab) positive;
- Positive for Treponema pallidum antibody (TP Ab);
- Positive human immunodeficiency virus (HIV) antibody test;
- EBV-DNA and CMV-DNA copy numbers are greater than the measurable lower limit;
- Individuals known to have a history of hypersensitivity reactions to the components of the formulation used in the experiment.
Who the study is looking for
- Age ≥ 14 years old;
- Diagnosed with CD19+B-cell acute lymphoblastic leukemia \[refer to the Chinese Guidelines for Diagnosis and Treatment of Adult Acute lymphoblastic Leukemia (2024 edition)\];
- Patients who have received treatment with CNCT-19.
Age in the registry: 14 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ruijin Hospital Shanghai Jiaotong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.